Literature DB >> 17443278

Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Kotaro Miyake1, Satoru Imura, Tomoharu Yoshizumi, Tetsuya Ikemoto, Yuji Morine, Mitsuo Shimada.   

Abstract

BACKGROUND: Thymidine phosphorylase (TP), orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase (DPD) are important enzymes related to the metabolism of 5-fluorouracil and its derivatives. In this study, we analyzed the expression of these enzymes and evaluated the association between the expression of these enzymes and clinicopathological features and prognosis in patients with pancreatic cancer.
METHODS: TP, OPRT, and DPD mRNA expressions were detected using a real-time reverse transcriptional-polymerase chain reaction method or by immunohistochemistry, using surgical specimens obtained from 25 patients with pancreatic cancer.
RESULTS: TP mRNA expression was lower in cases with an alpha infiltration growth pattern than in cases with other infiltration growth patterns (P < 0.05). OPRT mRNA expression was higher in poorly differentiated-type cases than in differentiated type cases (P < 0.05). TP-, OPRT-, and DPD-positive stainings were found in 15 of 24 cases (63%), 10 of 19 cases (53%), and 14 of 21 cases (67%), respectively. There were significant correlations or trends between the mRNA and protein expressions of TP, OPRT, and DPD. Patients with a low TP/DPD ratio survived significantly longer than those with a high ratio (P < 0.05). Multivariate analysis demonstrated a significantly poorer outcome in patients with a high TP/DPD ratio compared with in patients with a low ratio (P < 0.05).
CONCLUSION: The TP/DPD ratio might be useful as a prognostic factor in patients with pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17443278     DOI: 10.1007/s10147-006-0634-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  34 in total

1.  Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.

Authors:  Shingo Kamoshida; Hiroshi Matsuoka; Taro Ishikawa; Kotaro Maeda; Ryoichi Shimomura; Ken-ichi Inada; Yutaka Tsutsumi
Journal:  Jpn J Clin Oncol       Date:  2004-10       Impact factor: 3.019

2.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival.

Authors:  S Fujioka; K Yoshida; S Yanagisawa; M Kawakami; T Aoki; Y Yamazaki
Journal:  Cancer       Date:  2001-10-01       Impact factor: 6.860

4.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

Authors:  D V Santi; C S McHenry; H Sommer
Journal:  Biochemistry       Date:  1974-01-29       Impact factor: 3.162

5.  Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.

Authors:  Genichi Nishimura; Itsurou Terada; Takashi Kobayashi; Itasu Ninomiya; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Masato Kayahara; Koichi Shimizu; Tetsuo Ohta; Koichi Miwa
Journal:  Oncol Rep       Date:  2002 May-Jun       Impact factor: 3.906

Review 6.  Capecitabine: preclinical pharmacology studies.

Authors:  H Ishitsuka
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

7.  Purification and properties of an endothelial cell growth factor from human platelets.

Authors:  K Miyazono; T Okabe; A Urabe; F Takaku; C H Heldin
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

8.  Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil.

Authors:  Shingo Kamoshida; Hiroshi Matsuoka; Kazuya Shiogama; Atsuji Matsuyama; Ryoichi Shimomura; Ken-Ichi Inada; Morito Maruta; Yutaka Tsutsumi
Journal:  Pathol Int       Date:  2004-08       Impact factor: 2.534

9.  Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.

Authors:  Y Ishikawa; T Kubota; Y Otani; M Watanabe; T Teramoto; K Kumai; T Takechi; H Okabe; M Fukushima; M Kitajima
Journal:  Jpn J Cancer Res       Date:  2000-01

10.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Authors:  W Ichikawa; H Uetake; Y Shirota; H Yamada; T Takahashi; Z Nihei; K Sugihara; Y Sasaki; R Hirayama
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

View more
  13 in total

Review 1.  Recent studies of 5-fluorouracil resistance in pancreatic cancer.

Authors:  Wei-Bin Wang; Yu Yang; Yu-Pei Zhao; Tai-Ping Zhang; Quan Liao; Hong Shu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

2.  Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer.

Authors:  Ayako Nakamura; Kazuhiko Hayashi; Go Nakajima; Hirotaka Kamikozuru; Ryuji Okuyama; Hidekazu Kuramochi; Takashi Hatori; Masakazu Yamamoto
Journal:  Exp Ther Med       Date:  2011-08-22       Impact factor: 2.447

3.  A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.

Authors:  Christina H Wei; Tristan R Gorgan; David A Elashoff; O Joe Hines; James J Farrell; Timothy R Donahue
Journal:  Pancreas       Date:  2013-11       Impact factor: 3.327

4.  Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expression of fluoropyrimidine metabolism enzymes in the primary tumor.

Authors:  Masanori Matsuda; Shugo Shiba; Masami Asakawa; Hiroshi Kono; Hideki Fujii
Journal:  Int J Clin Oncol       Date:  2009-07-11       Impact factor: 3.402

5.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

6.  Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.

Authors:  Haiyan Lu; Robert S Klein; Edward L Schwartz
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

7.  Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer.

Authors:  Osamu Nakahara; Hiroshi Takamori; Hiroshi Tanaka; Yasuo Sakamoto; Yoshiaki Ikuta; Satoshi Furuhashi; Masayuki Watanabe; Toru Beppu; Masahiko Hirota; Keiichiro Kanemitsu; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2010-02       Impact factor: 3.402

8.  DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer.

Authors:  Hiroyuki Kato; Aya Naiki-Ito; Shugo Suzuki; Shingo Inaguma; Masayuki Komura; Kenju Nakao; Taku Naiki; Kenta Kachi; Akihisa Kato; Yoichi Matsuo; Satoru Takahashi
Journal:  Carcinogenesis       Date:  2021-07-16       Impact factor: 4.944

9.  Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-Fluorouracil in head and neck squamous cell carcinoma in vitro.

Authors:  Ryuji Yasumatsu; Torahiko Nakashima; Shizuo Komune
Journal:  J Oncol       Date:  2012-03-26       Impact factor: 4.375

10.  Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression.

Authors:  Jiongjia Cheng; John R Cashman
Journal:  Invest New Drugs       Date:  2020-09-11       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.